Extensive disease small cell lung cancer dose-response relationships: Implications for resistance mechanisms

Journal of Thoracic Oncology

Volumn 5, Issue 11, 2010, Pages 1826-1834

  Stewart, David J ^a   Johnson, Constance ^a   Lopez, Adriana ^a   Glisson, Bonnie ^a   Rhee, Jay M ^b   Bekele, B Nebiyou ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Dose response; Quiescence.; Resistance; Small cell

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CELL KILLING; CELL SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR CELL; TUMOR VOLUME;

EID: 78149468714     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f387c7     Document Type: Article

References (103)

1. Crivellari G, Monfardini S, Stragliotto S, et al. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. Oncologist 2007;12:79-89.
2. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366: 1385-1396.
3. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
4. Kurup A, Hanna NH. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 2004;52:117-126.
5. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004;30:521-543.
6. Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999; 25:199-206.
7. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
8. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;75:173-234.
9. Stewart DJ, Raaphorst GP, Yau J, et al. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 1996;14:115-130.
10. Stewart DJ, Chiritescu G, Dahrouge S, et al. Chemotherapy dose- response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 2007;33:101-137.
11. Miller A, Hogestraeten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
12. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
13. Aisner J, Whitacre MY, Budman DR, et al. Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemother Pharmacol 1992;29:435-438.
14. Asamoto H, Kawahara M, Iwami F, et al. Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group. Jpn J Clin Oncol 1998;28:745-748.
15. Chen YM, Wu MF, Perng RP, et al. Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer. Jpn J Clin Oncol 1997;27:76-79.
16. Clark PI, Slevin ML, Joel SP, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994;12:1427-1435.
17. Eckhardt S, Kolaric K, Vukas D, et al. Phase II study of 4'-epidoxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG). Med Oncol Tumor Pharmacother 1990;7:19-23.
18. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13: 1430-1435.
19. Fetscher S, Brugger W, Engelhardt R, et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. Ann Oncol 1999;10:605-607.
20. Frasci G, Nicolella G, Comella P, et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Br J Cancer 2001;84:1166-1171.
21. Gatzemeier U, Pawel JV, Laumen R, et al. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Semin Oncol 1994;21:31-35.
22. Glisson BS, Kurie JM, Perez-Soler R, et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 1999;17:2309-2315.
23. Glisson B, Lee JS, Palmer J, et al. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer 1998;82:301-308.
24. Greco FA, Murphy PB, Hainsworth JD, et al. Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. Oncology 1992;49(Suppl 1):34 -38; discussion 39.
25. Gridelli C, Perrone F, D'Aprile M, et al. Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocytecolony stimulating factor) in extensive small cell lung cancer. Eur J Cancer 1995;31A:2424-2426.
26. Gridelli C, Manzione L, Perrone F, et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 2001;84:38-41.
27. Gridelli C, Perrone F, Ianniello GP, et al. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensivestage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol 1998;16:1414-1419.
28. Gridelli C, Rossi A, Barletta E, et al. Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. Lung Cancer 2002;36:327-332.
29. Grunberg SM, Crowley J, Hande KR, et al. Treatment of poorprognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide-a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol 1999;44:461-468.
30. Hainsworth JD, Carrell D, Drengler RL, et al. Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2004;100:2437-2441.
31. Hasturk S, Kurt B, Kocabas A, et al. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer. J Chemother 1997;9:66-71.
32. Higano CS, Crowley JJ, Veith RV, et al. A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. Invest New Drugs 1997;15:153-156.
33. Johnson DH, Wolff SN, Hainsworth JD, et al. Extensive-stage smallcell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 1985;3:170-175.
34. Kanitz E, Kolaric K, Jassem J, et al. Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology 1992;49:327-332.
35. Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999;22:517-522.
36. Latreille J, Cormier Y, Martins H, et al. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 1996;13:343-345.
37. Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:2594-2599.
38. Luikart SD, Goutsou M, Mitchell ED, et al. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group. B. Am J Clin Oncol 1993;16:127-131.
39. Matsui K, Masuda N, Fukuoka M, et al. Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 1998;77:1961-1965.
40. Mavroudis D, Pavlakou G, Blazoyiannakis G, et al. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Lung Cancer 2003;39:71-76.
41. Miller AA, Herndon JE II, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination withintravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995;13:1871-1879.
42. Mitchell EP, Perry MC, Luikart SD, et al. A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. Lung Cancer 1996;15:215-223.
43. Murphy PB, Hainsworth JD, Greco FA, et al. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensivestage small cell lung cancer. Cancer 1992;69:370-375.
44. Negoro S, Masuda N, Furuse K, et al. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1997;40(Suppl):S70-S73.
45. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005;23:3752-3759.
46. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
47. Perez EA, Geoffroy FJ, Hillman S, et al. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer 2004;44:347-353.
48. Pujol JL, Douillard JY, Riviere A, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte- macrophage colony-stimulating factor in extensive-stage smallcell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997;15:2082-2089.
49. Saijo N, Horiike A. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience. Oncology (Williston Park) 2004;18: 11-16.
50. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996;14: 2345-2352.
51. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
52. Sculier JP, Paesmans M, Lecomte J, et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001;85:1444-1451.
53. Skarlos DV, Dimopoulos AM, Kosmidis P, et al. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer 2003;41:107-111.
54. Socinski MA, Neubauer MA, Olivares J, et al. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer 2003;40:91-97.
55. Sorensen BT, Nielsen K, Steenholdt S, et al. Treatment of extensive small cell lung cancer with carboplatin and teniposide. Eur J Cancer 1991;27:1109-1112.
56. Takigawa N, Fujiwara K, Ueoka H, et al. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res 2003;23:557-560.
57. Trillet-Lenoir V, Soler P, Arpin D, et al. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer. Lung Cancer 1996;14:331-341.
58. Viren M, Liippo K, Ojala A, et al. Carboplatin and etoposide in extensive small cell lung cancer. Acta Oncol 1994;33:921-924.
59. Stewart DJ, Nundy D, Maroun JA, et al. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 1985;69:269-273.
60. Stewart DJ. Lung cancer resistance to chemotherapy. In DJ Stewart (Ed.), Lung Cancer: Prevention, Management and Future Directions. New York: Humana Press, 2010, pp 331-393.
61. Banna GL, Simonelli M, Santoro A. High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. Curr Stem Cell Res Ther 2007;2:65-82.
62. Dimanche-Boitrel MT, Garrido C, Chauffert B. Kinetic resistance to anticancer agents. Cytotechnology 1993;12:347-356.
63. Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer 2005;93:302-309.
64. Jackson RC. The problem of the quiescent cancer cell. Adv Enzyme Regul 1989;29:27-46.
65. Liang XJ, Shen DW, Gottesman MM. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem 2004; 98:1599-1606.
66. Shen DW, Su A, Liang XJ, et al. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatinresistant cells. Br J Cancer 2004;91:270-276.
67. Liang XJ, Mukherjee S, Shen DW, et al. Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res 2006;66: 2346-2353.
68. Roberson RS, Kussick SJ, Vallieres E, et al. Escape from therapyinduced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005;65:2795-2803.
69. Ling YH, Zou Y, Perez-Soler R. Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res 2000;20:693-702.
70. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117:326-336.
71. Puig PE, Guilly MN, Bouchot A, et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 2008;32:1031-1043.
72. Matsui K, Sawa T, Suzuki H, et al. Relapse of stage I small cell lung cancer ten or more years after the start of treatment. Jpn J Clin Oncol 2006;36:457-461.
73. Sekine I, Nishiwaki Y, Kakinuma R, et al. Late recurrence of small-cell lung cancer: treatment and outcome. Oncology 1996;53:318-321.
74. Johnson BE, Ihde DC, Bunn PA, et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 1985;103:430-438.
75. Vogelsang GB, Abeloff MD, Ettinger DS, et al. Long-term survivors of small cell carcinoma of the lung. Am J Med 1985;79:49-56.
76. Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009;15: 3881-3888.
77. Durand RE, Vanderbyl SL. Schedule dependence for cisplatin and etoposide multifraction treatments of spheroids. J Natl Cancer Inst 1990;82:1841-1845.
78. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93.
79. Liu SQ, Yu JP, Yu HG, et al. Activation of Akt and ERK signaling pathways induced by etoposide confer chemoresistance in gastric cancer cells. Dig Liver Dis 2006;38:310-318.
80. Torigoe T, Izumi H, Ishiguchi H, et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005;5: 15-27.
81. Berghmans T, Paesmans M, Lafitte JJ, et al. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002;37: 115-123.
82. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852.
83. Buchholz E, Manegold C, Pilz L, et al. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol 2007;2:51-58.
84. Masutani M, Ochi Y, Kadota A, et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncol Rep 2000;7:305-310.
85. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival withoutreducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404.
86. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocytemacrophage colony-stimulating factor and dose intensification of VICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998;16:642-650.
87. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75:306-309.
88. Thatcher N, Qian W, Clark PI, et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005;23: 8371-8379.
89. Pujol JL, Daures JP, Riviere A, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-308.
90. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987;5:1864-1873.
91. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5: 1731-1738.
92. O'Donnell MR, Ruckdeschel JC, Baxter D, et al. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep 1985;69:571-575.
93. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308.
94. Urban T, Chastang C, Lebas FX, et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Cancer 1999;86: 2238-2245.
95. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993;11:1858-1865.
96. Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005;97:666-674.
97. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colonystimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 1998;16:2126-2132.
98. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-2034.
99. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002;20:3947-3955.
100. Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985;3:54-64.
101. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin- etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001;12:463-470.
102. Miyamoto H, Kawakami Y, Arimoto T, et al. [Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer]. Gan To Kagaku Ryoho 1991;18:1127-1134.
103. Jett JR, Everson L, Therneau TM, et al. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 1990;8:33-38.